12:08 PM EDT, 08/13/2025 (MT Newswires) -- Generation Bio ( GBIO ) shares surged 58% in recent Wednesday trading, a day after the company said it plans to cut the majority of its workforce and explore strategic alternatives.

Strategic restructuring will occur in phases from mid-August through the end of October, including a workforce reduction of about 90%.

The company added that it also started exploring strategic options to maximize shareholder value, with TD Cowen serving as its financial advisor. However, there's no guarantee that this process will lead to a deal, or that any transaction will happen, or on what terms.

The company reported a Q2 loss of $3.12 per share, compared with a loss of $3.07 per share a year earlier. Analysts surveyed by FactSet expected a loss of $2.85. Revenue was $765,000, down from $4.1 million a year earlier. Analysts polled by FactSet expected $2.5 million.

Generation Bio ( GBIO ) also released new data highlighting the potential of its cell-targeted lipid nanoparticle, or ctLNP, delivery system. The findings show that this system successfully delivered small interfering RNA specifically to T cells in non-human primates.

The delivery was highly selective and effective, well-tolerated after both single and repeat dosing, and did not trigger T cell activation.

The company said the results support the potential use of ctLNP for treating T cell-driven autoimmune diseases.

Price: 6.40, Change: +2.35, Percent Change: +58.02